Evidence map›Paper›PMID 41304759›Full record

ArticlePharmaceutics2025

Pharmacogenomic Drug-Target Network Analysis Reveals Similarity Profiles Among FDA-Approved Cancer Drugs.

Alberto Berral-González, Monica M Arroyo, Diego Alonso-López, María Jesús Rivas-López, José Manuel Sánchez-Santos, Javier De Las Rivas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alberto Berral-GonzálezCancer Research Center (CiC-IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Científicas (CSIC)/University of Salamanca (USAL), & Instituto de Investigación Biomédica de Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0001-8388-6051
Monica M ArroyoChemistry Department, Pontifical Catholic University of Puerto Rico (PCUPR), Ponce 00717, Puerto Rico.ORCID 0000-0001-8851-031X
Diego Alonso-LópezBioinformatics Unit, Cancer Research Center (CiC-IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Científicas (CSIC)/University of Salamanca (USAL), 37007 Salamanca, Spain.ORCID 0000-0003-1015-9923
María Jesús Rivas-LópezDepartment of Statistics, University of Salamanca (USAL), 37008 Salamanca, Spain.ORCID 0000-0003-0714-0519
José Manuel Sánchez-SantosCancer Research Center (CiC-IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Científicas (CSIC)/University of Salamanca (USAL), & Instituto de Investigación Biomédica de Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0002-7434-7598
Javier De Las RivasCancer Research Center (CiC-IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Científicas (CSIC)/University of Salamanca (USAL), & Instituto de Investigación Biomédica de Salamanca (IBSAL), 37007 Salamanca, Spain.ORCID 0000-0002-0984-9946

Funding

Instituto de Salud Carlos III (ISCiii, Ministerio de Ciencia, Innovación y Universidades, Spain) PI22/00877
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anticancer drugbioinformaticscancerdrugdrug–targetinteractomicsoncological pharmacologypharmacogenomicsprotein-drug network

Identifiers

PMID41304759
PMCPMC12655765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.